#United States #New York #Securities Fraud #Rosen Law Firm #Vistagen Therapeutics

Overview

Investors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) are being called to action by Rosen Law Firm, a well-known global law firm specializing in investor rights. If you purchased common stock of Vistagen between April 1, 2024, and December 16, 2025, you could be eligible to participate in a securities fraud class action lawsuit. Notably, the deadline to lead the class action is March 16, 2026. The firm emphasizes the importance of acting promptly to ensure your rights are protected.

What You Need to Know

The Rosen Law Firm urges all relevant investors to join the ongoing class action against Vistagen Therapeutics. Those who purchased shares within the specified timeframe may receive compensation without incurring any upfront costs, as the financial structure relies on a contingency fee arrangement. This means that you only pay if the case is successful.

To get involved, potential plaintiffs should visit the Rosen Law Firm’s website or contact Phillip Kim, Esq. at the toll-free number 866-767-3653. Participation as a lead plaintiff is crucial, as this person will represent the interests of all investors in the case proceedings.

The Basis of the Lawsuit

According to the lawsuit documents, the defendants allegedly misled investors by sharing excessively positive information regarding the company's investigational drug, fasedienol, intended for the treatment of social anxiety disorder (SAD). Vistagen made strong claims about the drug’s prospects based on favorable results from the earlier PALISADE-2 clinical trial.

However, as the lawsuit reveals, these assertions were made while important negative data and adverse facts about the ongoing Phase 3 PALISADE-3 trial were concealed. Once the actual situation was disclosed, it led to significant financial losses for investors. The legal case thus seeks to hold accountable those responsible for misleading shareholders.

Timing is Key

It is critical for investors to note that a class has yet to be certified. Until this certification, individuals looking to join the suit must enlist their own legal counsel or may choose to remain as absent class members without any action. The firm warns that a participant's chances of sharing in any future settlements are not contingent on taking on the role of lead plaintiff.

By positioning yourself strategically within this class action, you have the opportunity to potentially recover losses if the lawsuit is successful. The deadline for motioning as lead plaintiff is March 16, 2026, so proactive measures are advised.

The Rosen Law Firm’s Advocacy

Rosen Law Firm has built a reputation for advocating vigorously for investor rights, notably ranking highly in terms of securities class actions. The firm has previously secured substantial settlements for investors nationwide, including a record-breaking case against a Chinese firm. Their expertise and proven track record reinforce their commitment to successfully navigate investor challenges in the legal landscape.

Conclusion

Investors in Vistagen Therapeutics have a vital opportunity to participate in this class action lawsuit, with potential reparations available for those impacted by the alleged securities fraud. If you believe you qualify, do not hesitate to reach out for more information and take action accordingly. The legal landscape can be complex, but joining forces with a reputable firm like Rosen Law Firm can provide both expertise and representation.

Stay informed about updates related to this case by following the firm's accounts on LinkedIn and Twitter, where announcements and relevant news will be posted as the case progresses. For additional inquiries or concerns, get in touch with their legal representatives to ensure your participation is secure.